PARIS - Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx (cabozantinib) in combination with Bristol Myers Squibb's Opdivo (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1

Cabometyx in combination with Opdivo reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40-0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx in combination with Opdivo, median progression-free survival (PFS), the trial's primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41-0.64], p < 0.0001).

In addition, Cabometyx in combination with Opdivo demonstrated a superior objective response rate, with twice as many patients responding compared to sunitinib (56% vs. 27%; p

(C) 2020 Electronic News Publishing, source ENP Newswire